What is the recommended diagnostic work‑up and initial treatment for a patient with suspected inflammatory myositis, including management of severe weakness, dysphagia, or respiratory involvement?

Management of Suspected Inflammatory Myositis

Initiate high-dose corticosteroids at 0.5-1 mg/kg/day (typically 60-80 mg prednisone daily) immediately upon diagnosis, and concurrently start a steroid-sparing immunosuppressive agent such as methotrexate, azathioprine, or mycophenolate mofetil to optimize outcomes and minimize steroid toxicity. 1, 2

Diagnostic Work-Up

Essential Laboratory Evaluation

• Muscle enzymes: Measure CK, aldolase, AST, ALT, and LDH to quantify muscle inflammation 3, 2
• Cardiac assessment: Obtain troponin (troponin I is more specific than troponin T in skeletal muscle disease), ECG, and echocardiogram to exclude myocarditis—this is mandatory as myocarditis significantly increases mortality risk to ~20% versus <10% in idiopathic myositis 3, 2
• Inflammatory markers: Check ESR and CRP 3, 2
• Autoantibody panel: Test for myositis-specific antibodies and anti-AChR/antistriational antibodies to exclude myasthenia gravis overlap 3, 2
• Urinalysis: Screen for rhabdomyolysis 3

Clinical Examination Priorities

• Muscle strength testing: Focus on proximal muscle groups; weakness is more typical than pain 3
• Skin examination: Look for dermatomyositis features (Gottron's papules, heliotrope rash), though these are often absent initially 3, 4
• Bulbar symptoms: Assess for dysphagia, dysarthria, dysphonia—these indicate severe disease requiring aggressive treatment 3
• Respiratory function: Evaluate for respiratory muscle involvement 3
• Cardiac symptoms: Screen for dyspnea, palpitations, chest pain, or syncope suggesting myocarditis 3

Advanced Imaging and Testing (When Diagnosis Uncertain)

• MRI: Use T1-weighted, T2-weighted, and fat suppression sequences to detect muscle edema and monitor treatment response 1, 2
• EMG: Consider when overlap with neurologic syndromes is suspected 3
• Muscle biopsy: Reserve for uncertain diagnosis or suspected overlap syndromes 3

Initial Treatment Algorithm

Mild Disease (Grade 1)

Presentation: Mild weakness with or without pain, normal or minimally elevated CK

• Continue normal activities 2
• Offer acetaminophen or NSAIDs for myalgia if no contraindications 3, 2
• If CK elevated with muscle weakness: Initiate prednisone 0.5 mg/kg/day and treat as Grade 2 3

Moderate Disease (Grade 2)

Presentation: Moderate weakness limiting instrumental activities of daily living, CK ≥3× upper limit of normal

• Hold immune checkpoint inhibitors temporarily if applicable; may resume when symptoms controlled and prednisone <10 mg/day 3
• Initiate prednisone 0.5-1 mg/kg/day (typically 60-80 mg daily) 3, 1
• Concurrently start steroid-sparing agent: Methotrexate, azathioprine, or mycophenolate mofetil 1, 2, 5
• Refer to rheumatology or neurology 3
• Note: May require permanent discontinuation of checkpoint inhibitors in most patients with objective findings (elevated enzymes, abnormal EMG/MRI/biopsy) 3

Severe Disease (Grade 3-4)

Presentation: Severe weakness limiting self-care, respiratory involvement, dysphagia, or myocardial involvement

• Hospitalize immediately 2
• Initiate prednisone 1 mg/kg/day orally OR methylprednisolone 1-2 mg/kg IV 1, 2
• Consider IV methylprednisolone pulse therapy: 10-20 mg/kg or 250-1000 mg daily for 1-5 consecutive days 1
• Add intravenous immunoglobulin (IVIG): Supported by controlled studies in dermatomyositis and effective in polymyositis 1, 6
• For life-threatening manifestations: Consider cyclophosphamide 1
• For refractory cases: Consider rituximab or cyclosporine 1
• Permanently discontinue checkpoint inhibitors if any myocardial involvement 3, 5

Corticosteroid Tapering Protocol

Begin tapering after 2-4 weeks of clinical response: 1, 2

• Reduce by 10 mg every 2 weeks until reaching 30 mg/day
• Then reduce by 5 mg every 2 weeks until reaching 20 mg/day
• Finally reduce by 2.5 mg every 2 weeks to maintenance dose ≤10 mg/day 1

Monitoring Strategy

Regular Follow-Up Assessment

• Muscle enzyme levels: CK, aldolase at each visit 1, 2
• Inflammatory markers: ESR, CRP 1, 2
• Clinical muscle strength testing at each visit 2
• MRI imaging to assess treatment response 1, 2
• Cardiac monitoring: Repeat troponin and ECG if any cardiac symptoms develop 3

Prevention of Steroid-Related Complications

• Bone health: DEXA scans to detect osteoporosis early 1
• Calcium and vitamin D supplementation for all patients on long-term glucocorticoids 1
• Bisphosphonate therapy if osteoporosis develops 1
• PCP prophylaxis: Trimethoprim-sulfamethoxazole for patients receiving ≥20 mg prednisone daily for ≥4 weeks 1

Critical Pitfalls to Avoid

Life-Threatening Complications

• Myocarditis is the primary cause of death in checkpoint inhibitor-related myositis and must be systematically evaluated in every suspected myositis case 3
• Normal cardiac enzymes cannot always rule out myocarditis—maintain high clinical suspicion 3
• Cardiac MRI is necessary if clinical syndrome, elevated troponin, or ECG changes are present 3

Common Management Errors

• Failure to screen for malignancy in adult patients, especially with dermatomyositis 1, 5
• Inadequate initial corticosteroid dosing—must use 0.5-1 mg/kg/day, not lower doses 1, 5
• Delaying initiation of steroid-sparing agents—these should be started concurrently with corticosteroids, not sequentially 1, 5
• Missing myasthenia gravis overlap—occurs in 12.5% of cases and requires specific autoantibody testing 3

Special Populations

• Checkpoint inhibitor-related myositis: Occurs early (median 25 days after initiation), frequently associated with myocarditis and/or myasthenia gravis, and has higher mortality than idiopathic myositis 3
• Approximately 10% of checkpoint inhibitor myositis patients require IV methylprednisolone pulses 3, 1
• Up to 20% may require IVIG and ~10% may need plasma exchange 3